• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Incyte Corp. (Amendment)

    2/14/23 2:03:59 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $INCY alert in real time by email
    SC 13G/A 1 d650496dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (AMENDMENT NO. 1)*

     

     

    INCYTE CORPORATION

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    45337C102

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. 45337C102    13G    PAGE 2 OF 4 PAGES

     

      1   

    NAME OF REPORTING PERSON

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Dodge & Cox    94-1441976

      2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)  ☐        (b)  ☐

     

    N/A

      3   

      SEC USE ONLY

     

      4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    California - U.S.A.

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

          5     

    SOLE VOTING POWER

     

    18,209,985

          6     

    SHARED VOTING POWER

     

    0

          7     

    SOLE DISPOSITIVE POWER

     

    19,362,935

          8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    19,362,935

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

    N/A

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    8.7%

    12   

    TYPE OF REPORTING PERSON*

     

    IA


    Item 1(a)

    Name of Issuer:

    INCYTE CORPORATION

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices:

    1801 Augustine Cut-Off

    Wilmington, Delaware 19803

     

    Item 2(a)

    Name of Person Filing:

    Dodge & Cox

     

    Item 2(b)

    Address of the Principal Office or, if none, Residence:

    555 California Street, 40th Floor

    San Francisco, CA 94104

     

    Item 2(c)

    Citizenship:

    California - U.S.A.

     

    Item 2(d)

    Title of Class of Securities:

    Common Stock

     

    Item 2(e)

    CUSIP Number:

    45337C102

     

    Item 3

    If the Statement is being filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

    (e) ☒ Investment Advisor registered under section 203 of the Investment Advisors Act of 1940

     

    Item 4

    Ownership:

     

      (a)

    Amount Beneficially Owned:

    19,362,935

     

      (b)

    Percent of Class:

    8.7%


      (c)

    Number of shares as to which such person has:

     

      (i)

    sole power to vote or direct the vote:

    18,209,985

     

      (ii)

    shared power to vote or direct the vote:

    0

     

      (iii)

    sole power to dispose or to direct the disposition of:

    19,362,935

     

      (iv)

    shared power to dispose or to direct the disposition of:

    0

     

    Item 5

    Ownership of Five Percent or Less of a Class:

    Not applicable.

     

    Item 6

    Ownership of More than Five Percent on Behalf of Another Person:

    The clients of Dodge & Cox, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, INCYTE CORPORATION.

    Dodge & Cox Stock Fund, an investment company registered under the Investment Company Act of 1940, has an interest of 12,002,300, or 5.4%, of the class of securities reported herein.

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

    Not applicable.

     

    Item 8

    Identification and Classification of Members of the Group:

    Not applicable.

     

    Item 9

    Notice of Dissolution of a Group:

    Not applicable.

     

    Item 10

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2023            

     

    DODGE & COX
    By:  

    /S/ Katherine M. Primas

    Name:   Katherine M. Primas
    Title:   Chief Compliance Officer
    Get the next $INCY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INCY

    DatePrice TargetRatingAnalyst
    8/6/2025$89.00Equal Weight → Overweight
    Wells Fargo
    8/1/2025$90.00Overweight
    Barclays
    6/16/2025$107.00Hold → Buy
    Stifel
    3/18/2025Buy → Neutral
    Guggenheim
    3/18/2025Outperform → Mkt Perform
    William Blair
    12/17/2024$77.00Neutral
    UBS
    10/29/2024$68.00 → $90.00Neutral → Buy
    BofA Securities
    10/1/2024$84.00Outperform
    Wolfe Research
    More analyst ratings

    $INCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & General Counsel Denton Sheila A. exercised 277 shares at a strike of $64.25 and sold $24,046 worth of shares (277 units at $86.81) (SEC Form 4)

    4 - INCYTE CORP (0000879169) (Issuer)

    8/19/25 4:13:11 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    EVP & General Counsel Denton Sheila A. exercised 598 shares at a strike of $58.06 and sold $45,310 worth of shares (598 units at $75.77) (SEC Form 4)

    4 - INCYTE CORP (0000879169) (Issuer)

    8/6/25 4:03:10 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    New insider Mayes Patrick A claimed ownership of 67,388 shares (SEC Form 3)

    3 - INCYTE CORP (0000879169) (Issuer)

    8/5/25 4:03:49 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Incyte to Present at Upcoming Investor Conferences

    Incyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of September: Cantor Global Healthcare Conference on Wednesday, September 3, 2025 at 8:00 am (EDT) Well Fargo Healthcare Conference on Thursday, September 4, 2025 at 8:45 am (EDT) Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 10:00 am (EDT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs.

    8/19/25 8:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis

    - Company initiates search for successor and reaffirms full year financial guidance Incyte (NASDAQ:INCY) today announced that Christiana Stamoulis will step down from her role as Executive Vice President and Chief Financial Officer (CFO) to pursue another opportunity, effective September 16, 2025. Ms. Stamoulis will remain with the Company until then to support a smooth transition. The Company has initiated the process of appointing a successor. "Since joining Incyte in 2019, Christiana has been an invaluable part of the leadership team. I would like to take this opportunity to thank Christiana for her many contributions, and wish her well in her future endeavors," said Bill Meury, Pres

    8/5/25 4:05:00 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America

    MONTREAL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX:GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has expanded its existing relationship and amended its agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), for the exclusive rights to distribute retifanlimab (sold as ZYNYZ® in the United States and Europe) and axatilimab (sold as NIKTIMVO™ in the United States) in Latin America. Under the terms of the amended agreement Incyte will be responsible for the development, manufacture and supply to Knight of retifanlimab and axatilimab, and Knight will be responsible for

    8/4/25 4:30:00 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for JAKAFI issued to INCYTE CORP

    Submission status for INCYTE CORP's drug JAKAFI (SUPPL-25) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/27/2021. Application Category: NDA, Application Number: 202192, Application Classification: Labeling

    9/28/21 5:20:01 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    FDA Approval for JAKAFI issued to INCYTE CORP

    Submission status for INCYTE CORP's drug JAKAFI (SUPPL-23) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/22/2021. Application Category: NDA, Application Number: 202192, Application Classification: Efficacy

    9/23/21 5:11:12 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    FDA Approval for OPZELURA issued to INCYTE CORP

    Submission status for INCYTE CORP's drug OPZELURA (ORIG-1) with active ingredient RUXOLITINIB has changed to 'Approval' on 09/21/2021. Application Category: NDA, Application Number: 215309, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    9/22/21 11:16:23 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Incyte upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Incyte from Equal Weight to Overweight and set a new price target of $89.00

    8/6/25 7:56:54 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Barclays initiated coverage on Incyte with a new price target

    Barclays initiated coverage of Incyte with a rating of Overweight and set a new price target of $90.00

    8/1/25 8:13:12 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte upgraded by Stifel with a new price target

    Stifel upgraded Incyte from Hold to Buy and set a new price target of $107.00

    6/16/25 7:42:04 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Leadership Updates

    Live Leadership Updates

    View All

    Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

    - Three-decade industry leader, former CEO of Karuna and Anthos and Chief Commercial Officer of Allergan, Bill Meury, joins Incyte as President and CEO - Hervé Hoppenot to retire after 11 years of leading Incyte through major expansion - Julian Baker elected Chairman of the Board of Directors Incyte (NASDAQ:INCY) today announced that the Company's Board of Directors has unanimously appointed Bill Meury as President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors, effective immediately. Bill Meury succeeds Hervé Hoppenot who will retire from the Company after 11 years of service. Mr. Hoppenot will serve as an advisor to the CEO and will remain as a

    6/26/25 7:30:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board

    Mechelen, Belgium; 12 June 2023, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that during its meeting of 12 June 2023, the Board of Directors co-opted Dr. Susanne Schaffert as non-executive independent Director. Dr. Schaffert replaces Dr. Rajesh Parekh who stepped down on 10 June 2023. After an extraordinary 27-year career at Novartis in various global roles, including commercialization, market access, investor relations, business development & licensing, acquisitions and company integration, Dr. Schaffert retired in 2022 as President of Novartis Oncology and Member of the Novartis Executive Committee. In that role, Dr. Schaffert ran a global $15 billion business acr

    6/12/23 4:01:00 PM ET
    $GLPG
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Incyte Names New Member to Its Board of Directors

    Incyte (NASDAQ:INCY) announces the appointment of Susanne Schaffert, Ph.D., as a new member of its Board of Directors. "On behalf of the Incyte Board of Directors, I am happy to welcome Susanne. Her extensive commercial, development and industry experience will greatly complement our Board and we look forward to Susanne's contributions to our continued growth and future success," said Hervé Hoppenot, Chief Executive Officer, Incyte. "I am very excited for the opportunity to join the Incyte Board of Directors and helping the organization in its commitment to leading scientific innovation and developing new medicines for patients in need. I look forward to being part of this dynamic Company

    10/4/22 8:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Financials

    Live finance-specific insights

    View All

    Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

    – Total revenues of $1,216 million in the second quarter (Q2'25) (+16% Y/Y); total product revenues of $1,059 million in Q2'25 (+17%Y/Y) – Jakafi® (ruxolitinib) net product revenues of $764 million in Q2'25 (+8% Y/Y); raising full year 2025 guidance to a new range of $3,000 - $3,050 million [previously $2,950 - $3,000 million] – Opzelura® (ruxolitinib) cream net product revenues of $164 million in Q2'25 (+35% Y/Y) – Niktimvo™ (axatilimab-csfr) net product revenues of $36 million in the second quarter, demonstrating strong commercial execution; raising full year 2025 Other Oncology guidance to a new range of $500 - $520 million [previously $415 - $455 million] – Zynyz® (retifanlimab-

    7/29/25 7:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte to Report Second Quarter Financial Results

    Incyte (NASDAQ:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 29, 2025. The schedule for the press release and conference call/webcast is as follows: Q2 2025 Press Release: July 29, 2025 at 7:00 a.m. ET Q2 2025 Conference Call: July 29, 2025 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13754581 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-6

    7/10/25 8:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

    Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and restoring normal blood cell production In high-risk patients with essential thrombocythemia (ET) with a CALR mutation (mutCALR), 86% of INCA033989-treated patients at doses 400 mg and above achieved a complete or partial hematologic response with the majority (82%) realizing a complete response A reduction in peripheral blood mutCALR variant allele frequency (VAF) was observed in 89% of evaluable patients correlating with hematologic response Initial results demonstrate a favorable safety profile – no dose limiting toxicit

    6/15/25 3:15:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Incyte Corp.

    SC 13G - INCYTE CORP (0000879169) (Subject)

    10/17/24 9:39:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13D/A filed by Incyte Corp.

    SC 13D/A - INCYTE CORP (0000879169) (Subject)

    6/14/24 6:23:05 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Incyte Corp. (Amendment)

    SC 13D/A - INCYTE CORP (0000879169) (Subject)

    5/13/24 6:06:33 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    SEC Filings

    View All

    SEC Form 144 filed by Incyte Corp.

    144 - INCYTE CORP (0000879169) (Subject)

    8/12/25 4:21:26 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Corp. filed SEC Form 8-K: Leadership Update

    8-K - INCYTE CORP (0000879169) (Filer)

    8/7/25 9:08:14 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-Q filed by Incyte Corp.

    10-Q - INCYTE CORP (0000879169) (Filer)

    7/29/25 4:01:59 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care